Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that CEO David Cory will present a corporate update at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that CEO David Cory will present a corporate update at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 PM EDT. A live webcast will be available on Eiger's website, with a replay accessible one hour after the event. Eiger specializes in targeted therapies for rare diseases, with key programs focusing on Hepatitis Delta Virus and its FDA-approved product, Zokinvy®, for Hutchinson-Gilford Progeria Syndrome. The company will also conduct virtual one-on-one meetings with investors.
Details
News Market Reaction – EIGR
The recorded move for EIGR in the trading session of this news was +1.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM EDT.
A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger will also host virtual one-on-one meetings with investors.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.
Zokinvy® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
Sri Ryali
Chief Financial Officer
Email: sryali@eigerbio.com
Phone: 1-650-272-6138
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-2021-301300252.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.